Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Tenax Therapeutics, Inc.NASDAQ: TENX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $5.03M fell 11.0% year over year, behind the +106.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 14.8% from the prior quarter. Over 3 fiscal years it compounded at +61.1% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +249.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.03M-14.8% QoQ
- Last fiscal yearDec 2025
- $23.71M+249.5% YoY
- LTMMar 2026
- $23.09M+106.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -11.0% | -100.0% | -89.0 pp |
| 1 year | +249.5% | -100.0% | -349.5 pp |
| 3-year CAGR | +61.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 23.71M USD
- Year-over-year change
- +249.5%
- 4-year CAGR
- +33.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.71M | +249.5% |
| FY2024 | 2024-12-31 | 6.79M | +35.6% |
| FY2023 | 2023-12-31 | 5.01M | -11.8% |
| FY2022 | 2022-12-31 | 5.68M | -25.1% |
| FY2021 | 2021-12-31 | 7.58M | — |
Selling, General & Admin vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's LTM Mar 2026 selling, general & admin of $23.09M is the 3rd highest of the 7 companies compared; the peer median is $20.03M.
- Its year-over-year change of +106.1% is the 3rd highest of 7, against a peer median of -5.5%.
- Over three fiscal years its annual growth of +61.1% compares with a peer median of +11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.42B | +118480.6% | -4.1% | — | |
| LTM Mar 2026 | $36.36M | -29.2% | +26.5% | 97.8% | |
| LTM Mar 2026 | $23.09M | +106.1% | +61.1% | — | |
| LTM Jun 2026 | $21.82M | +116.7% | -3.8% | — | |
| LTM Mar 2026 | $18.25M | -6.2% | +26.2% | — | |
| LTM Mar 2026 | $17.08M | -4.8% | +20.7% | 31.8% | |
| LTM Mar 2026 | $13.3M | -6.8% | +1.5% | — | |
| Peer median (excluding TENX) | $20.03M | -5.5% | +11.1% | 64.8% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.15M | 5.38M | 3.23M | 12.71M | 32.67M |
| Selling, General & Admin | 7.58M | 5.68M | 5.01M | 6.79M | 23.71M |
| Operating Expenses | 32.73M | 11.05M | 8.23M | 19.49M | 56.39M |
| Depreciation & Amortization | 108.98K | 113.33K | 8K | 0 | 0 |
| EBITDA | (32.36M) | (10.93M) | (7.68M) | (17.58M) | (52.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (32.73M) | (11.05M) | (8.23M) | (19.49M) | (56.39M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 1.91M | 3.82M |
| Interest Expense | 949 | 4.44K | 23.97K | 23K | 0 |
| Other Income / Expenses | 253.88K | 4.75K | 523K | 1.89M | 3.79M |
| Income Before Tax | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2,524.80) | (600.80) | (31.09) | (1.15) | (1.34) |
| EPS (Diluted) | (2,524.80) | (600.80) | (31.04) | (1.15) | (1.34) |
| Weighted Avg Shares | 12.86K | 18.39K | 248K | 15.27M | 39.22M |
| Weighted Avg Shares (Diluted) | 12.86K | 18.39K | 248.45K | 15.27M | 39.22M |
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.